Daiichi Sankyo And Aussie Biotech Biota Begin Phase III Asian Trials For Second-Generation Flu Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-acting second-generation LANIs have a compliance advantage in once-only for treatment and once-weekly for prophylaxis dosing.